Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPIA | P62937 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.45 |
| ▸ | PTPRC | P08575 | 1/20 | 0.45 |
| ▸ | PTPRB | P23467 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 2/20 | 0.44 |
| ▸ | RXRB | P28702 | 2/20 | 0.44 |
| ▸ | RXRG | P48443 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2575343 | 0.86 | LIPE (0.43) | RXRARXRBRXRGDRD2DRD1 | |
| SCHEMBL31041187 | 0.86 | SLC6A9 (0.47) | DRD2DRD1SGMS2ALDH1A1LMNA | |
| SCHEMBL2580807 | 0.86 | PPIA (0.47) | PPIAPTPN1PTPN6RXRARXRB | |
| SCHEMBL477534 | 0.85 | DRD2 (0.55) | DRD2DRD1SGMS2ALDH1A1LMNA | |
| SCHEMBL2579112 | 0.84 | RXRA (0.46) | RXRARXRBRXRGDRD2DRD1 | |
| SCHEMBL2577640 | 0.82 | SGMS2 (0.54) | PPIARXRARXRBDRD2DRD1 | |
| SCHEMBL2578523 | 0.82 | SGMS2 (0.54) | RXRARXRBRXRGDRD2DRD1 | |
| SCHEMBL2577406 | 0.82 | LIPE (0.46) | RXRARXRBDRD2DRD1SGMS2 | |
| SCHEMBL2575133 | 0.82 | DRD2 (0.46) | DRD2DRD1SGMS2ALDH1A1LMNA | |
| SCHEMBL1539311 | 0.81 | LIPE (0.45) | RXRARXRBRXRGDRD2DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8048897-B2 | Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-11-01 | — | — | US | disclosed |
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
| US-7414072-B2 | Aryl 5-thio-β-d-glucopyranoside derivatives and therapeutic agents for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-08-19 | — | — | US | disclosed |
| US-7250522-B2 | Method for selective preparation of aryl 5-thio-β-D-aldohexopyranosides | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2007-07-31 | — | — | US | disclosed |
| EP-1783110-A1 | NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-05-09 | — | — | EP | disclosed |
| US-20050256317-A1 | Process for selective production of aryl 5-thio-beta-d- aldohexopyranosides | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| US-20050209309-A1 | Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-22 | — | — | US | disclosed |
| EP-1541578-A1 | PROCESS FOR SELECTIVE PRODUCTION OF ARYL 5-THIO-BETA-D-ALDOHEXOPYRANOSIDES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-1528066-A1 | ARYL 5-THIO-D-GLUCOPYRANOSIDE DERIVATIVES AND REMEDIES FOR DIABETES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2005-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318874-A1 | Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes | SLC5A1, GPR119, SLC5A2 | PPIA 3257/4885PTPN1 215/4885PTPN2 528/4885 |
| US-20050256317-A1 | Process for selective production of aryl 5-thio-beta-d- aldohexopyranosides | ALDOA, DERA, AKR1D1 | PPIA 2566/4885PTPN1 284/4885PTPN2 298/4885 |
| US-20050209309-A1 | Aryl 5-thio-beta-d-glucopyranoside derivatives and remedies for diabetes containing the same | SLC5A2, SLC5A1, UGGT1 | PPIA 2790/4885PTPN1 371/4885PTPN2 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.